loading
Schlusskurs vom Vortag:
$3.24
Offen:
$3.21
24-Stunden-Volumen:
793.17K
Relative Volume:
1.27
Marktkapitalisierung:
$206.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-5.7054
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+5.06%
1M Leistung:
-26.14%
6M Leistung:
-57.89%
1J Leistung:
+127.37%
1-Tages-Spanne:
Value
$3.15
$3.32
1-Wochen-Bereich:
Value
$3.02
$3.365
52-Wochen-Spanne:
Value
$1.39
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Firmenname
Corvus Pharmaceuticals Inc
Name
Telefon
(650) 900-4520
Name
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Name
Mitarbeiter
31
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
CRVS's Discussions on Twitter

Vergleichen Sie CRVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
3.185 206.45M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.75 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.78 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.54 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
230.40 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
228.75 26.16B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-02 Eingeleitet H.C. Wainwright Buy
2023-08-18 Eingeleitet Oppenheimer Outperform
2021-12-01 Fortgesetzt Jefferies Buy
2021-05-27 Eingeleitet Cantor Fitzgerald Overweight
2021-02-10 Herabstufung Mizuho Buy → Neutral
2019-09-12 Eingeleitet Mizuho Buy
2019-05-29 Eingeleitet ROTH Capital Buy
2017-08-24 Hochstufung Credit Suisse Underperform → Neutral
2017-05-01 Herabstufung Credit Suisse Neutral → Underperform
2016-04-18 Eingeleitet Credit Suisse Outperform
2016-04-18 Eingeleitet Guggenheim Buy
Alle ansehen

Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten

pulisher
01:05 AM

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister

01:05 AM
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints New Director to Board - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - TradingView

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN

Apr 07, 2025
pulisher
Mar 29, 2025

Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st

Mar 27, 2025
pulisher
Mar 27, 2025

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable

Mar 27, 2025
pulisher
Mar 26, 2025

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus: Q4 Earnings Snapshot - Greenwich Time

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq

Mar 25, 2025
pulisher
Mar 23, 2025

CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 21, 2025

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter

Mar 21, 2025
pulisher
Mar 20, 2025

Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 19, 2025
pulisher
Mar 19, 2025

Corvus Pharma Reveals Autoimmune Pipeline Strategy at Major HC Wainwright Conference - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times

Mar 18, 2025
pulisher
Mar 17, 2025

Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan

Mar 17, 2025
pulisher
Mar 16, 2025

Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday - The AM Reporter

Mar 16, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian

Mar 12, 2025
pulisher
Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News

Mar 12, 2025
pulisher
Mar 03, 2025

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha

Mar 03, 2025
pulisher
Feb 26, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter

Feb 26, 2025

Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Kapitalisierung:     |  Volumen (24h):